Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Addressing challenges of clinical trials in acute pain: The Pain Management of Vaso-occlusive Crisis in Children and Young Adults with Sickle Cell Disease Study
source: Clinical Trials
year: 2016
authors: Nottage KA, Hankins JS, Faughnan LG, James DM, Richardson J, Christensen R, Kang G, Smeltzer M, Cancio MI, Wang WC, Anghelescu DL
summary/abstract:BACKGROUND/AIMS:
Neuropathic pain is a known component of vaso-occlusive pain in sickle cell disease; however, drugs targeting neuropathic pain have not been studied in this population. Trials of acute pain are complicated by the need to obtain consent, to randomize participants expeditiously while optimally treating pain. We describe the challenges in designing and implementing the Pain Management of Vaso-occlusive Crisis in Children and Young Adults with Sickle Cell Disease Study (NCT01954927), a phase II, randomized, double-blind, placebo-controlled trial to determine the effect of gabapentin for vaso-occlusive crisis.
METHODS:
In the Pain Management of Vaso-occlusive Crisis in Children and Young Adults with Sickle Cell Disease Study, we aim to assess the analgesic effect of gabapentin during vaso-occlusive crisis. Difficulties we identified included avoiding delay of notification of study staff of potential participants which we resolved by automated notification. Concern for rapid randomization and drug dispensation was addressed through careful planning with an investigational pharmacy and a single liquid formulation. We considered obtaining consent during well-visits to avoid the time constraints with acute presentations, but the large number of patients and limited duration that consent is valid made this impractical.
RESULTS:
In all, 79% of caregivers/children approached have agreed to participate. The trial is currently active, and enrollment is at 45.8% of that targeted (76 of 166) and expected to continue for two more years. Maintaining staff availability after-hours remains problematic, with 8% of screened patients missed for lack of available staff.
LESSONS LEARNED:
Lessons learned in designing a trial to expedite procedures in the acute pain setting include (1) building study evaluations upon a standard-of-care backbone; (2) implementing a simple study design to facilitate consent and data capture; (3) assuring ample, well-trained study staff; and (4) utilizing technology to automate procedures whenever possible.
CONCLUSION:
This study design has circumvented many of the logistical barriers usually associated with acute pain trials and may serve as a prototype for future studies.
DOI: 10.1177/1740774516636573
read more full text
Related Content
-
Novel Use of Hydroxyurea in an African Region With Malaria: Protocol for a Randomized Controlled Clinical TrialBackground: Sickle cell anemia (SCA), ...
-
Restrictive cardiomyopathy is associated with nephropathy in sickle cell anemiaBackground: Cardiopulmonary and renal c...
-
CIRM and NHLBI Collaborating to Fund Cell and Gene Therapies for Sickle Cell DiseaseThe California Institute for Regenerativ...
-
Study challenges view that sickle cell trait increases mortality riskSurprising findings from a study of heal...
-
Sickle Cell Anemia Toddlers Benefit from Maximal Hydroxyurea Doses, Study FindsIntensifying treatment with hydroxyurea ...
-
Fighting Through Our Pain TV with Thomas J. Harrington MDhttps://www.youtube.com/watch?time_conti...
-
Improving the Lives of People with Sickle Cell Diseasehttps://www.youtube.com/watch?v=NPaV0glX...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.